Francesco Bonì

Mr. Francesco Bonì

University of Milan
+1
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Antiviral Research
Verified
Journal Article
Open access
Mario MilaniMario Milani
Mario Milani
MDManuela Donalisio
Manuela Donalisio
RBRafaela Milan Bonotto
Rafaela Milan Bonotto
ESEdoardo Schneider
Edoardo Schneider
IAIrene Arduino
Irene Arduino
EMEloise Mastrangelo
Eloise Mastrangelo
The current emergency of the novel coronavirus SARS-CoV2 urged the need for broad-spectrum antiviral drugs as the first line of treatment. Coronaviruses are a large family of viruses that already challenged humanity in at least two other previous outbreaks and are likely to be a constant threat for the future. In this work we developed a pipeline based on in silico docking of known drugs on SARS-CoV1/2 RNA-dependent RNA polymerase combined with in vitro antiviral assays on both SARS-CoV2 and the common cold human coronavirus HCoV-OC43. Results showed that certain drugs displayed activity for both viruses at a similar inhibitory concentration, while others were specific. In particular, the antipsychotic drug lurasidone and the antiviral drug elbasvir showed promising activity in the low micromolar range against both viruses with good selectivity index.

23 October 2017 in Human Molecular Genetics
Verified
Journal Article
Open access
FBFrancesco Bonì
Francesco Bonì
Mario MilaniMario Milani
Mario Milani
ABAlberto Barbiroli
Alberto Barbiroli
Luisa DiomedeLuisa Diomede
Luisa Diomede
EMEloise Mastrangelo
Eloise Mastrangelo
MRMatteo de Rosa
Matteo de Rosa
AGel amyloidosis is a genetic degenerative disease characterized by the deposition of insoluble gelsolin protein aggregates in different tissues. Until recently, this disease was associated with two mutations of a single residue (Asp187 to Asn/Tyr) in the second domain of the protein. The general opinion is that pathogenic variants are not per se amyloidogenic but rather that the mutations trigger an aberrant proteolytic cascade, which results in the production of aggregation prone fragments. Here, we report the crystal structure of the second domain of gelsolin carrying the recently identified Gly167Arg mutation. This mutant dimerizes through a three-dimensional domain swapping mechanism, forming a tight but flexible assembly, which retains the structural topology of the monomer. To date, such dramatic conformational changes of this type have not been observed. Structural and biophysical characterizations reveal that the Gly167Arg mutation alone is responsible for the monomer to dimer transition and that, even in the context of the full-length protein, the pathogenic variant is prone to form dimers. These data suggest that, in addition to the well-known proteolytic-dependent mechanism, an alternative oligomerization pathway may participate in gelsolin misfolding and aggregation. We propose to integrate this alternative pathway into the current model of the disease that may also be relevant for other types of AGel amyloidosis, and other related diseases with similar underlying pathological mechanisms.

16 September 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FBFrancesco Bonì
Francesco Bonì
Mario MilaniMario Milani
Mario Milani
RPRiccardo Porcari
Riccardo Porcari
ABAlberto Barbiroli
Alberto Barbiroli
Stefano RicagnoStefano Ricagno
Stefano Ricagno
MRMatteo de Rosa
Matteo de Rosa
Mutations in gelsolin are responsible for a systemic amyloidosis first described in 1969. Until recently, the disease was associated with two substitutions of the same residue, leading to the loss of the calcium binding site. Novel interest arose in 2014 when the N184K variant of the protein was identified as the etiological agent of a novel kidney-localized amyloidosis. Here we provide a first rationale for N184K pathogenicity. We show that the mutation induces a destabilization of gelsolin second domain, without compromising its calcium binding capacity. X-ray data combined with molecular dynamics simulations demonstrates that the primary source of the destabilization is a loss of connectivity in proximity of the metal. Such rearrangement of the H-bond network does not have a major impact on the overall fold of the domain, nevertheless, it increases the flexibility of a stretch of the protein, which is consequently processed by furin protease. Overall our data suggest that the N184K variant is subjected to the same aberrant proteolytic events responsible for the formation of amyloidogenic fragments in the previously characterized mutants. At the same time our data suggest that a broader number of mutations, unrelated to the metal binding site, can lead to a pathogenic phenotype.

5 October 2020 in Biomolecules
Verified
Journal Article
Open access
PDF file
FBFrancesco Bonì
Francesco Bonì
VMValerio Marino
Valerio Marino
CBCarlo Bidoia
Carlo Bidoia
EMEloise Mastrangelo
Eloise Mastrangelo
ABAlberto Barbiroli
Alberto Barbiroli
Mario MilaniMario Milani
Mario Milani
The guanylyl cyclase-activating protein 1, GCAP1, activates or inhibits retinal guanylyl cyclase (retGC) depending on cellular Ca2+ concentrations. Several point mutations of GCAP1 have been associated with impaired calcium sensitivity that eventually triggers progressive retinal degeneration. In this work, we demonstrate that the recombinant human protein presents a highly dynamic monomer-dimer equilibrium, whose dissociation constant is influenced by salt concentration and, more importantly, by protein binding to Ca2+ or Mg2+. Based on small-angle X-ray scattering data, protein-protein docking, and molecular dynamics simulations we propose two novel three-dimensional models of Ca2+-bound GCAP1 dimer. The different propensity of human GCAP1 to dimerize suggests structural differences induced by cation binding potentially involved in the regulation of retGC activity.

29 March 2019 in Amyloid
Verified
Journal Article
Closed access
FBFrancesco Bonì
Francesco Bonì
Mario MilaniMario Milani
Mario Milani
EMEloise Mastrangelo
Eloise Mastrangelo
ABAlberto Babiroli
Alberto Babiroli
Luisa DiomedeLuisa Diomede
Luisa Diomede
MRMatteo de Rosa
Matteo de Rosa
(2019). An alternative non-proteolytic mechanism may underlie AGel amyloidosis. Amyloid: Vol. 26, Proceedings of the XVI International Symposium on Amyloidosis Kumamoto, Japan 26-29 March 2018, pp. 150-151.

1 July 2026 in Asian Journal of Organic Chemistry
Verified
Journal Article
Open access
EFElisa Fagnani
Elisa Fagnani
PCPaolo Cocomazzi
Paolo Cocomazzi
WGWaldemar Goldeman
Waldemar Goldeman
MSMarcin Sieńczyk
Marcin Sieńczyk
FBFrancesco Bonì
Francesco Bonì
FCFederica Cossu
Federica Cossu
Homeostasis in organisms is regulated by apoptosis, whose dysregulation in neoplastic cells is often associated with overexpression of inhibitor of apoptosis proteins (IAPs). IAPs inhibit caspases, key executors of apoptosis. Smac (Second Mitochondria‐derived Activator of Caspases), counteracts this inhibition by binding to a specific groove in IAPs, enabling caspase activation. Smac‐mimetics (SMs) are small molecules antagonizing IAPs and are promising antitumor agents. As IAP homologues employ distinct mechanisms to regulate cell death, SMs binding can lead to different molecular outcomes. We report the synthesis and characterization of two novel SMs — a bivalent ( 6 ) and a monovalent ( 7 ) derivative — exhibiting one or two mimic heads and a phosphoroorganic moiety. Their effects on cIAP1 and XIAP were analyzed combining thermal stability, affinity analysis, size exclusion chromatography, and virtual docking. Both compounds selectively target cIAP1‐BIR3 over XIAP and interact with the BIR2 and BIR3 domains of XIAP via intramolecular binding, highlighting the phosphoroorganic moiety's ability to engage BIR2. In contrast, the bivalent 6 induces cIAP1 dimerization through intermolecular binding. These findings support the rational design of novel IAP antagonists with predictable effects, emphasizing selectivity and the potential to induce distinct molecular responses, including those mediated by bifunctional proteolysis‐targeting chimera (PROTAC) compounds.